Diabetes Antibody Standardization Program: First Assay Proficiency Evaluation

Diabetes - Tập 52 Số 5 - Trang 1128-1136 - 2003
Polly J. Bingley1, Ezio Bonifacio2, Patricia W. Mueller3
1Division of Medicine, University of Bristol, Bristol, U.K.
2Istitutio Scientifico San Raffaele, Milan, Italy
3Centers for Disease Control and Prevention, Atlanta, Georgia

Tóm tắt

The aims of the first proficiency evaluation of the Diabetes Antibody Standardization Program (DASP) were to assess general implementation of assay methods and to evaluate the new World Health Organization (WHO) reference reagent for autoantibodies to GAD and IA-2. Forty-six laboratories in 13 countries received coded sera from 50 patients with newly diagnosed type 1 diabetes and 50 blood donor control subjects, together with the WHO reference reagent and diluent serum. Results were analyzed using receiver operator characteristic (ROC) curves. Sensitivity was adjusted to 90% specificity in workshop controls. The median adjusted sensitivity for GADA (45 laboratories) was 84% (range 62–96%), for IA-2A (43 laboratories) was 58% (50–74%), and for insulin autoantibody (IAA; 23 laboratories) was 36% (13–66%). ROC curve analysis showed all GADA and IA-2A assays, and 18/23 IAA assays found significant differences between patients and control subjects. There was good concordance between laboratories in ranking of samples by GADA and IA-2A levels or if results were expressed in relation to the WHO reference reagent. Assays that achieved the highest sensitivity for IAA were also concordant in ranking samples, but overall concordance for IAA was poor. Differences in assay protocols between laboratories must be addressed so that all centers and kit manufacturers can perform to the same high standard.

Từ khóa


Tài liệu tham khảo

Bingley PJ, Bonifacio E, Ziegler AG, Schatz DA, Atkinson MA, Eisenbarth GS on behalf of the Immunology of Diabetes Society: Proposed guidelines in screening for risk of type 1 diabetes. Diabetes Care 24: 398–398,2001

Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R, UK Prospective Diabetes Study Group: UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350: 1288–1293,1997

The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20: 1183–1197,1997

Ziegler AG, Hummel M, Schenker M, Bonifacio E: Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB study. Diabetes 48: 460–468,1999

Rewers M, Bugawan TL, Norris JM, Blair A, Beaty B, Hoffman M, McDuffie RS, Hamman RF, Klingensmith G, Eisenbarth GS, Erlich HA: Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 39: 807–812,1996

Bonifacio E, Boitard C, Gleichman H, Shattock MA, Molenaar JL, Bottazzo GF: Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurements in 41 assays. Diabetologia 33: 731–736,1990

Bottazzo GF, Gleichmann H: Immunology and Diabetes Workshops: report of the First International Workshop on Standardisation of Cytoplasmic Islet Cell Antibodies. Diabetologia 29: 125–126,1986

Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ, Eisenbarth GS: Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 47: 1857–1866,1998

Mire-Sluis AR, Gaines Das R, Lernmark Å: The World Health Organization International Collaborative Study for islet cell antibodies. Diabetologia 43: 1282–1292,2000

Williams AJK, Bingley PJ, Bonifacio E, Palmer JP, Gale EAM: A novel micro-assay for insulin autoantibodies. J Autoimmun 10: 473–478,1997

Naserke HE, Dozio N, Ziegler AG, Bonifacio E: Comparison of a novel micro-assay for insulin autoantibodies with the conventional radiobinding assay. Diabetologia 41: 681–683,1998

Yu L, Robles DT, Abiru N, Kaur P, Rewers M, Kelemen K, Eisenbarth GS: Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes. Proc Natl Acad Sci U S A 97: 1701–1706,2000

Vardi P, Dib SA, Tuttleman M, Connelly JE, Grinbergs M, Radizabeh A, Riley WJ, Maclaren NK, Eisenbarth GS, Soeldner JS: Competitive insulin autoantibody assay: prospective evaluation of subjects at high risk for development of type 1 diabetes mellitus. Diabetes 36: 1286–1291,1987